Genes, CRISPR, and Next

Human genome project revealed a complete mapping of over 20,000 human genes, and the information tremendously helps us to deepen our understanding of over 7,000 genetic disorders. Recent progress in gene sequencing technology further allowed us to read individual genomes with an affordable cost, and its analysis enabled us to predict risks of developing certain disorders at unprecedented levels.


CRISPR was originally discovered in late 1980s as an immune system for bacteria to fight against their intruders. However, it was re-invented as gene editing tools for mammalian genomes in 2012. Skyrocketed number of studies have been reported since then, with ever-rising expectation to apply this technology for developing human therapeutics leveraging its potential to precisely target and modify disease causing genes.



Then what is the next move?



It is natural consequence that people want to treat genetic disorders by correcting the disease-causing gene with the new genome editing tools. So…

About EdiGENE


Modalis Therapeutics, formerly EdiGENE, is an emerging biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo.


Our mission is to deliver novel therapeutics for monogenic disorders which are caused by a gene which loses normal function or gains malfunction, and yet cannot be managed, treated or cured with existing therapeutic modalities.


Modalis Therapeutics Corporation is headquartered in Tokyo Japan, with main operations conducted at Modalis Therapeutics Inc. in Cambridge MA, USA, a heart of innovation for biomedical science.

Our Team

Haru Morita,
President, CEO and co-founder

Haru is the exuberant entrepreneur as well as the dynamic investor whose leadership and strategic vision drives EdiGENE toward success from his co-foundation in 2016. He brings more than 20 years of biotech industry leadership experience, most recently serving 8 years as president and CEO of REGiMMUNE, the company he founded to leverage the power of regulatory T cells to manage difficult-to-treat immune conditions such as GVHD (now in clinical trials). Before that Haru took a leading role in business development at Y’s Therapeutics that aspired for a novel biotherapeutics using xxx technology. As a scientist Haru played a pioneering role in the research and development of throasmbopoietin (aka TPO or MGDF) at KIRIN (merged into Kyowa-Hakko KIRIN). He acquired extensive business and consulting experiences at Booz Allen Hamilton (merged into Strategy & of PwC) where he engaged in numerous projects across various industry sectors.

Osamu Nureki, PhD
Co-founder, Board Member and Scientific Advisor

Professor Nureki is a world-renown structural biologist who has published numerous articles on prestigious scientific journals in the CRISPR field (e.g. Cell, 2014, 2015 & 2016). Dr. Nureki has a long-lasting collaboration relationship with Dr. Feng Zhang at Broad Institute, one of the key discoverers of CRISPR technology. Dr. Nureki and Dr. Zhang co-publish many scientific papers and co-file key critical patents on CRISPR and gene editing technologies. Dr. Nureki receives his PhD from University of Tokyo. He is currently a Professor at Department of Biophysics and Biochemistry, Graduate School of Science in the University of Tokyo.

[Link to Nureki Lab]

Hideki Takeda
Board Member

Representative partner at Medical Patent Research

Hideki is assisting early and established biotech companies to build their intellectual property strategies. He also serves on the board of directors of Healios KK, the company he has co-founded and now is listed on Japanese Mothers market. Prior to Healios, Hideki engaged in operations including the development of intellectual property strategies at Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.) and the Foundation for Biomedical Research and Innovation.

Tomohiro Anzai, PhD
Board Member

Managing Partner, Fast Track Initiative

He specializes into investments and management support for early-stage biotech start-ups. Prior to joining Fast Track Initiative, Dr. Anzai started his professional career at Arthur D. Little, a global management consulting firm.

Dr. Anzai earned his doctoral degree in Life Science from the University of Tokyo. In addition, Dr. Anzai serves as a Project Associate Professor of Translational Research Initiative in the University of Tokyo. In 2012, he was serving as a part-time member of Medical Innovation Office, Cabinet Secretariat of the Japanese Government.

He is currently on the board of directors of several biotech companies including AccuRna Inc., NB Health Laboratory, and Modulus Discovery, Inc.

Teruhisa Tajima
Corporate Auditor

Representing Director, Tajima CPA office.

Teruhisa has over 20 yrs experience in accounting and corporate finance. He has worked at Pricewaterhouse Coopers and the Shimizu Patent Office to consultant for start-ups, supporting their growth and successful emergence via M&A or IPOs. He has been served as external auditor of The Longreach Group and CYBIRD Holdings Co., Ltd. and has supported many biotechnology start-ups including Quantum Biosystems.

Tetsuya Yamagata, MD, PhD
Senior Director, Head of Science

Tetsuya leads R&D at EdiGENE to transform CRISPR technology into innovative medicine. Tetsuya is an accomplished scientist who has an extensive biomedical expertise in academic, clinic and bioindustry settings. Tetsuya joined EdiGENE in 2016 from GlaxoSmithKline where he had a leadership role in developing medicine against immune-mediated disorders. Prior to GSK, Tetsuya led a high-throughput biology team in the target discovery technology platform at Tempero Pharmaceutical (later acquired by GSK). Prior to Tempero, Tetsuya was an Associate Professor in Medicine at Dokkyo Medical University in Japan. Tetsuya received his MD and PhD from the University of Tokyo. He completed his internship and fellowship in hematology and oncology at Tokyo University Hospital. Tetsuya did his post-doctoral research at the University of Tokyo, and was an Instructor in Medicine at Harvard Medical School.


Boston Lab

MODALIS Inc. 51 Moulton St, Cambridge, MA 02138

Tokyo Office

MODALIS Corp. 16-5 Nihonbashikabutochō, Chuo City, Tōkyō-to 103-0026, Japan

Contact Form